Loading…
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer
Purpose Among gynecologic malignancies, ovarian cancer has the highest mortality due to rapid peritoneal dissemination. Treatment failure particularly arises from failure to eliminate disseminated cells. Our aim was to develop peptidic radioligands targeting tumour cell-associated urokinase receptor...
Saved in:
| Published in: | European journal of nuclear medicine and molecular imaging 2008, Vol.35 (1), p.53-64 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c342t-b252695440e3ae5a15f64c793e6a6bb6422a5ea8d6932c1128df7e983b48b7293 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c342t-b252695440e3ae5a15f64c793e6a6bb6422a5ea8d6932c1128df7e983b48b7293 |
| container_end_page | 64 |
| container_issue | 1 |
| container_start_page | 53 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 35 |
| creator | Knör, Sebastian Sato, Sumito Huber, Timo Morgenstern, Alfred Bruchertseifer, Frank Schmitt, Manfred Kessler, Horst Senekowitsch-Schmidtke, Reingard Magdolen, Viktor Seidl, Christof |
| description | Purpose
Among gynecologic malignancies, ovarian cancer has the highest mortality due to rapid peritoneal dissemination. Treatment failure particularly arises from failure to eliminate disseminated cells. Our aim was to develop peptidic radioligands targeting tumour cell-associated urokinase receptor (uPAR, CD87) for α-emitter therapy for advanced ovarian cancer.
Methods
DOTA-conjugated, uPAR-directed ligands were synthesised on solid-phase. Binding of peptides to human cells expressing uPAR was assayed by flow cytofluorometry or, in case of
213
Bi-labelled peptides, by measuring cell-bound radioactivity. Bio-distribution of the
213
Bi-labelled peptide P-P4D was analysed in nude mice 28 days after intraperitoneal inoculation of OV-MZ-6 ovarian cancer cells in the absence or presence of the plasma expander gelofusine.
Results
uPAR-selective ligands were developed based on published high-affinity uPAR-binding peptides. For preparation of
N
-terminally cross-linked divalent ligands, a novel solid-phase procedure was developed. Specific binding of
213
Bi-labelled peptides to monocytoid U937 and OV-MZ-6 cells was demonstrated using the natural ligand of uPAR, pro-uPA, or a soluble form of uPAR, suPAR, as competitors. The pseudo-symmetrical covalent dimer
213
Bi-P-P4D displayed superior binding to OV-MZ-6 cells in vitro. Accumulation of
213
Bi-P-P4D in tumour tissue was demonstrated by bio-distribution analysis in nude mice bearing intraperitoneal OV-MZ-6-derived tumours. Gelofusine reduced kidney uptake of
213
Bi-P-P4D by half.
Conclusion
Ovarian cancer cells overexpressing uPAR were specifically targeted in vitro and in vivo by
213
Bi-P-P4D. Kidney uptake of
213
Bi-P-P4D was distinctly reduced using gelofusine. Thus, this radiopeptide may represent a promising option for therapy for disseminated ovarian cancer. |
| doi_str_mv | 10.1007/s00259-007-0582-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70088225</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70088225</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-b252695440e3ae5a15f64c793e6a6bb6422a5ea8d6932c1128df7e983b48b7293</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS0Eoj_wAGyQVwgWAf_kx15WLRSkSiAEa2viTIJLYgfbuVIfix1PwTPh23sFO1ZzNOebI9mHkGecveaMdW8SY6LRVZEVa5So5ANyyluuq44p_fCv7tgJOUvpljGuhNKPyQnvlOZSy1Py6wp3OId1QZ8p-IHiDuYNsguehpGuuGY3OEtnNxU30Qxxwuz8RPO2hC1WkFKwDjIOdIvhu_OQkK4zpMX5MKGnYLPbQQ6RRrQlroiX26eLz6_oWORWaOfp758VLi5njDR_wwjr3b07uJTK3t_Hhx1EB55a8BbjE_JohDnh0-M8J1_fvf1y-b66-Xj94fLiprKyFrnqRSNa3dQ1QwnYAG_GtradlthC2_dtLQQ0CGpotRSWc6GGsUOtZF-rvhNanpMXh9w1hh8bpmwWlyzOM3gMWzIdY0oJ0RSQH0AbQ0oRR7NGt0C8M5yZfV3mUJfZy31dRpab58fwrV9w-Hdx7KcA4gCkYvkJo7ktn-7Lg_-T-gcptKW9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70088225</pqid></control><display><type>article</type><title>Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer</title><source>Springer Link</source><creator>Knör, Sebastian ; Sato, Sumito ; Huber, Timo ; Morgenstern, Alfred ; Bruchertseifer, Frank ; Schmitt, Manfred ; Kessler, Horst ; Senekowitsch-Schmidtke, Reingard ; Magdolen, Viktor ; Seidl, Christof</creator><creatorcontrib>Knör, Sebastian ; Sato, Sumito ; Huber, Timo ; Morgenstern, Alfred ; Bruchertseifer, Frank ; Schmitt, Manfred ; Kessler, Horst ; Senekowitsch-Schmidtke, Reingard ; Magdolen, Viktor ; Seidl, Christof</creatorcontrib><description>Purpose
Among gynecologic malignancies, ovarian cancer has the highest mortality due to rapid peritoneal dissemination. Treatment failure particularly arises from failure to eliminate disseminated cells. Our aim was to develop peptidic radioligands targeting tumour cell-associated urokinase receptor (uPAR, CD87) for α-emitter therapy for advanced ovarian cancer.
Methods
DOTA-conjugated, uPAR-directed ligands were synthesised on solid-phase. Binding of peptides to human cells expressing uPAR was assayed by flow cytofluorometry or, in case of
213
Bi-labelled peptides, by measuring cell-bound radioactivity. Bio-distribution of the
213
Bi-labelled peptide P-P4D was analysed in nude mice 28 days after intraperitoneal inoculation of OV-MZ-6 ovarian cancer cells in the absence or presence of the plasma expander gelofusine.
Results
uPAR-selective ligands were developed based on published high-affinity uPAR-binding peptides. For preparation of
N
-terminally cross-linked divalent ligands, a novel solid-phase procedure was developed. Specific binding of
213
Bi-labelled peptides to monocytoid U937 and OV-MZ-6 cells was demonstrated using the natural ligand of uPAR, pro-uPA, or a soluble form of uPAR, suPAR, as competitors. The pseudo-symmetrical covalent dimer
213
Bi-P-P4D displayed superior binding to OV-MZ-6 cells in vitro. Accumulation of
213
Bi-P-P4D in tumour tissue was demonstrated by bio-distribution analysis in nude mice bearing intraperitoneal OV-MZ-6-derived tumours. Gelofusine reduced kidney uptake of
213
Bi-P-P4D by half.
Conclusion
Ovarian cancer cells overexpressing uPAR were specifically targeted in vitro and in vivo by
213
Bi-P-P4D. Kidney uptake of
213
Bi-P-P4D was distinctly reduced using gelofusine. Thus, this radiopeptide may represent a promising option for therapy for disseminated ovarian cancer.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-007-0582-3</identifier><identifier>PMID: 17891393</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Alpha Particles - therapeutic use ; Animals ; Bismuth - chemistry ; Cardiology ; Cell Line, Tumor ; Dimerization ; Drug Discovery ; Enzyme Inhibitors - chemistry ; Female ; Gene Expression Regulation, Neoplastic ; Heterocyclic Compounds, 1-Ring - chemistry ; Humans ; Imaging ; Kidney - drug effects ; Kidney - metabolism ; Ligands ; Medicine ; Medicine & Public Health ; Mice ; Neoplasm Metastasis ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - radiotherapy ; Peptides - chemical synthesis ; Peptides - chemistry ; Peptides - metabolism ; Peptides - pharmacokinetics ; Polygeline - pharmacology ; Radioisotopes ; Radiology ; Receptors, Urokinase Plasminogen Activator - antagonists & inhibitors ; Receptors, Urokinase Plasminogen Activator - chemistry ; Receptors, Urokinase Plasminogen Activator - metabolism ; Solubility ; Substrate Specificity ; Tissue Distribution</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2008, Vol.35 (1), p.53-64</ispartof><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-b252695440e3ae5a15f64c793e6a6bb6422a5ea8d6932c1128df7e983b48b7293</citedby><cites>FETCH-LOGICAL-c342t-b252695440e3ae5a15f64c793e6a6bb6422a5ea8d6932c1128df7e983b48b7293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17891393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knör, Sebastian</creatorcontrib><creatorcontrib>Sato, Sumito</creatorcontrib><creatorcontrib>Huber, Timo</creatorcontrib><creatorcontrib>Morgenstern, Alfred</creatorcontrib><creatorcontrib>Bruchertseifer, Frank</creatorcontrib><creatorcontrib>Schmitt, Manfred</creatorcontrib><creatorcontrib>Kessler, Horst</creatorcontrib><creatorcontrib>Senekowitsch-Schmidtke, Reingard</creatorcontrib><creatorcontrib>Magdolen, Viktor</creatorcontrib><creatorcontrib>Seidl, Christof</creatorcontrib><title>Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Among gynecologic malignancies, ovarian cancer has the highest mortality due to rapid peritoneal dissemination. Treatment failure particularly arises from failure to eliminate disseminated cells. Our aim was to develop peptidic radioligands targeting tumour cell-associated urokinase receptor (uPAR, CD87) for α-emitter therapy for advanced ovarian cancer.
Methods
DOTA-conjugated, uPAR-directed ligands were synthesised on solid-phase. Binding of peptides to human cells expressing uPAR was assayed by flow cytofluorometry or, in case of
213
Bi-labelled peptides, by measuring cell-bound radioactivity. Bio-distribution of the
213
Bi-labelled peptide P-P4D was analysed in nude mice 28 days after intraperitoneal inoculation of OV-MZ-6 ovarian cancer cells in the absence or presence of the plasma expander gelofusine.
Results
uPAR-selective ligands were developed based on published high-affinity uPAR-binding peptides. For preparation of
N
-terminally cross-linked divalent ligands, a novel solid-phase procedure was developed. Specific binding of
213
Bi-labelled peptides to monocytoid U937 and OV-MZ-6 cells was demonstrated using the natural ligand of uPAR, pro-uPA, or a soluble form of uPAR, suPAR, as competitors. The pseudo-symmetrical covalent dimer
213
Bi-P-P4D displayed superior binding to OV-MZ-6 cells in vitro. Accumulation of
213
Bi-P-P4D in tumour tissue was demonstrated by bio-distribution analysis in nude mice bearing intraperitoneal OV-MZ-6-derived tumours. Gelofusine reduced kidney uptake of
213
Bi-P-P4D by half.
Conclusion
Ovarian cancer cells overexpressing uPAR were specifically targeted in vitro and in vivo by
213
Bi-P-P4D. Kidney uptake of
213
Bi-P-P4D was distinctly reduced using gelofusine. Thus, this radiopeptide may represent a promising option for therapy for disseminated ovarian cancer.</description><subject>Alpha Particles - therapeutic use</subject><subject>Animals</subject><subject>Bismuth - chemistry</subject><subject>Cardiology</subject><subject>Cell Line, Tumor</subject><subject>Dimerization</subject><subject>Drug Discovery</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Heterocyclic Compounds, 1-Ring - chemistry</subject><subject>Humans</subject><subject>Imaging</subject><subject>Kidney - drug effects</subject><subject>Kidney - metabolism</subject><subject>Ligands</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Neoplasm Metastasis</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - radiotherapy</subject><subject>Peptides - chemical synthesis</subject><subject>Peptides - chemistry</subject><subject>Peptides - metabolism</subject><subject>Peptides - pharmacokinetics</subject><subject>Polygeline - pharmacology</subject><subject>Radioisotopes</subject><subject>Radiology</subject><subject>Receptors, Urokinase Plasminogen Activator - antagonists & inhibitors</subject><subject>Receptors, Urokinase Plasminogen Activator - chemistry</subject><subject>Receptors, Urokinase Plasminogen Activator - metabolism</subject><subject>Solubility</subject><subject>Substrate Specificity</subject><subject>Tissue Distribution</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1TAQhS0Eoj_wAGyQVwgWAf_kx15WLRSkSiAEa2viTIJLYgfbuVIfix1PwTPh23sFO1ZzNOebI9mHkGecveaMdW8SY6LRVZEVa5So5ANyyluuq44p_fCv7tgJOUvpljGuhNKPyQnvlOZSy1Py6wp3OId1QZ8p-IHiDuYNsguehpGuuGY3OEtnNxU30Qxxwuz8RPO2hC1WkFKwDjIOdIvhu_OQkK4zpMX5MKGnYLPbQQ6RRrQlroiX26eLz6_oWORWaOfp758VLi5njDR_wwjr3b07uJTK3t_Hhx1EB55a8BbjE_JohDnh0-M8J1_fvf1y-b66-Xj94fLiprKyFrnqRSNa3dQ1QwnYAG_GtradlthC2_dtLQQ0CGpotRSWc6GGsUOtZF-rvhNanpMXh9w1hh8bpmwWlyzOM3gMWzIdY0oJ0RSQH0AbQ0oRR7NGt0C8M5yZfV3mUJfZy31dRpab58fwrV9w-Hdx7KcA4gCkYvkJo7ktn-7Lg_-T-gcptKW9</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>Knör, Sebastian</creator><creator>Sato, Sumito</creator><creator>Huber, Timo</creator><creator>Morgenstern, Alfred</creator><creator>Bruchertseifer, Frank</creator><creator>Schmitt, Manfred</creator><creator>Kessler, Horst</creator><creator>Senekowitsch-Schmidtke, Reingard</creator><creator>Magdolen, Viktor</creator><creator>Seidl, Christof</creator><general>Springer-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2008</creationdate><title>Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer</title><author>Knör, Sebastian ; Sato, Sumito ; Huber, Timo ; Morgenstern, Alfred ; Bruchertseifer, Frank ; Schmitt, Manfred ; Kessler, Horst ; Senekowitsch-Schmidtke, Reingard ; Magdolen, Viktor ; Seidl, Christof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-b252695440e3ae5a15f64c793e6a6bb6422a5ea8d6932c1128df7e983b48b7293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Alpha Particles - therapeutic use</topic><topic>Animals</topic><topic>Bismuth - chemistry</topic><topic>Cardiology</topic><topic>Cell Line, Tumor</topic><topic>Dimerization</topic><topic>Drug Discovery</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Heterocyclic Compounds, 1-Ring - chemistry</topic><topic>Humans</topic><topic>Imaging</topic><topic>Kidney - drug effects</topic><topic>Kidney - metabolism</topic><topic>Ligands</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Neoplasm Metastasis</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - radiotherapy</topic><topic>Peptides - chemical synthesis</topic><topic>Peptides - chemistry</topic><topic>Peptides - metabolism</topic><topic>Peptides - pharmacokinetics</topic><topic>Polygeline - pharmacology</topic><topic>Radioisotopes</topic><topic>Radiology</topic><topic>Receptors, Urokinase Plasminogen Activator - antagonists & inhibitors</topic><topic>Receptors, Urokinase Plasminogen Activator - chemistry</topic><topic>Receptors, Urokinase Plasminogen Activator - metabolism</topic><topic>Solubility</topic><topic>Substrate Specificity</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knör, Sebastian</creatorcontrib><creatorcontrib>Sato, Sumito</creatorcontrib><creatorcontrib>Huber, Timo</creatorcontrib><creatorcontrib>Morgenstern, Alfred</creatorcontrib><creatorcontrib>Bruchertseifer, Frank</creatorcontrib><creatorcontrib>Schmitt, Manfred</creatorcontrib><creatorcontrib>Kessler, Horst</creatorcontrib><creatorcontrib>Senekowitsch-Schmidtke, Reingard</creatorcontrib><creatorcontrib>Magdolen, Viktor</creatorcontrib><creatorcontrib>Seidl, Christof</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knör, Sebastian</au><au>Sato, Sumito</au><au>Huber, Timo</au><au>Morgenstern, Alfred</au><au>Bruchertseifer, Frank</au><au>Schmitt, Manfred</au><au>Kessler, Horst</au><au>Senekowitsch-Schmidtke, Reingard</au><au>Magdolen, Viktor</au><au>Seidl, Christof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2008</date><risdate>2008</risdate><volume>35</volume><issue>1</issue><spage>53</spage><epage>64</epage><pages>53-64</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Purpose
Among gynecologic malignancies, ovarian cancer has the highest mortality due to rapid peritoneal dissemination. Treatment failure particularly arises from failure to eliminate disseminated cells. Our aim was to develop peptidic radioligands targeting tumour cell-associated urokinase receptor (uPAR, CD87) for α-emitter therapy for advanced ovarian cancer.
Methods
DOTA-conjugated, uPAR-directed ligands were synthesised on solid-phase. Binding of peptides to human cells expressing uPAR was assayed by flow cytofluorometry or, in case of
213
Bi-labelled peptides, by measuring cell-bound radioactivity. Bio-distribution of the
213
Bi-labelled peptide P-P4D was analysed in nude mice 28 days after intraperitoneal inoculation of OV-MZ-6 ovarian cancer cells in the absence or presence of the plasma expander gelofusine.
Results
uPAR-selective ligands were developed based on published high-affinity uPAR-binding peptides. For preparation of
N
-terminally cross-linked divalent ligands, a novel solid-phase procedure was developed. Specific binding of
213
Bi-labelled peptides to monocytoid U937 and OV-MZ-6 cells was demonstrated using the natural ligand of uPAR, pro-uPA, or a soluble form of uPAR, suPAR, as competitors. The pseudo-symmetrical covalent dimer
213
Bi-P-P4D displayed superior binding to OV-MZ-6 cells in vitro. Accumulation of
213
Bi-P-P4D in tumour tissue was demonstrated by bio-distribution analysis in nude mice bearing intraperitoneal OV-MZ-6-derived tumours. Gelofusine reduced kidney uptake of
213
Bi-P-P4D by half.
Conclusion
Ovarian cancer cells overexpressing uPAR were specifically targeted in vitro and in vivo by
213
Bi-P-P4D. Kidney uptake of
213
Bi-P-P4D was distinctly reduced using gelofusine. Thus, this radiopeptide may represent a promising option for therapy for disseminated ovarian cancer.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>17891393</pmid><doi>10.1007/s00259-007-0582-3</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2008, Vol.35 (1), p.53-64 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70088225 |
| source | Springer Link |
| subjects | Alpha Particles - therapeutic use Animals Bismuth - chemistry Cardiology Cell Line, Tumor Dimerization Drug Discovery Enzyme Inhibitors - chemistry Female Gene Expression Regulation, Neoplastic Heterocyclic Compounds, 1-Ring - chemistry Humans Imaging Kidney - drug effects Kidney - metabolism Ligands Medicine Medicine & Public Health Mice Neoplasm Metastasis Nuclear Medicine Oncology Original Article Orthopedics Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Ovarian Neoplasms - radiotherapy Peptides - chemical synthesis Peptides - chemistry Peptides - metabolism Peptides - pharmacokinetics Polygeline - pharmacology Radioisotopes Radiology Receptors, Urokinase Plasminogen Activator - antagonists & inhibitors Receptors, Urokinase Plasminogen Activator - chemistry Receptors, Urokinase Plasminogen Activator - metabolism Solubility Substrate Specificity Tissue Distribution |
| title | Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T22%3A50%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20evaluation%20of%20peptidic%20ligands%20targeting%20tumour-associated%20urokinase%20plasminogen%20activator%20receptor%20(uPAR)%20for%20use%20in%20%CE%B1-emitter%20therapy%20for%20disseminated%20ovarian%20cancer&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Kn%C3%B6r,%20Sebastian&rft.date=2008&rft.volume=35&rft.issue=1&rft.spage=53&rft.epage=64&rft.pages=53-64&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-007-0582-3&rft_dat=%3Cproquest_cross%3E70088225%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c342t-b252695440e3ae5a15f64c793e6a6bb6422a5ea8d6932c1128df7e983b48b7293%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70088225&rft_id=info:pmid/17891393&rfr_iscdi=true |